Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02131428 · ClinicalTrials.gov registry record
Depression and Heart Failure Disease Progression
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 186
- Enrollment target
NCT02131428: Completed study, sponsored by Duke University.
NCT02131428 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 186 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02131428 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 186 participants
- Enrollment target
Study Summary
Heart failure is the most costly diagnosis in the Medicare population. Clinical depression is strikingly common in heart failure patients, and not only diminishes their quality of life, but also is associated with a markedly increased risk of hospitalization or death. This study is designed to further our understanding of the behavioral and biological effects of depression in patients with heart failure, so that appropriate treatments can be developed.
Primary Outcome
Time to hospitalization or death
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2014-11 |
| Est. Completion | 2021-12-01 |
What the finished NCT02131428 record still lists
NCT02131428 is an observational study that tracks outcomes without assigning an intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02131428 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02131428 about?
NCT02131428 is a clinical study titled "Depression and Heart Failure Disease Progression". Heart failure is the most costly diagnosis in the Medicare population. Clinical depression is strikingly common in heart failure patients, and not only diminishes their quality of life, but also is associated with a markedly increased risk of hospitalization or death. This study is designed to furth...
What is the current status of trial NCT02131428?
This trial is currently completed. The enrollment target is 186 participants. The study started on 2014-11. Estimated completion is 2021-12-01.
Who is sponsoring clinical trial NCT02131428?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia